CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.3% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2026 Apr 07, 22:10

Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 72,559 Shares

Vir Biotechnology Inc
Webhose 2026 Apr 04, 20:24

Is Vir Biotechnology's (VIR) Insider Selling After Its Capital Raise Reframing the Investment Narrative?

Vir Biotechnology Inc
Webhose 2026 Apr 02, 16:57

Vir Biotechnology (NASDAQ:VIR) Director Sells $199,540.00 in Stock

Vir Biotechnology Inc
Webhose 2026 Mar 28, 09:00

Nordea Investment Management AB Sells 104,835 Shares of Vir Biotechnology, Inc. $VIR - Markets Daily

Vir Biotechnology Inc
Webhose 2026 Mar 26, 07:22

Vir Biotechnology (NASDAQ:VIR) CAO Brent Sabatini Sells 7,711 Shares of Stock - Stock Observer

Vir Biotechnology Inc
Webhose 2026 Mar 25, 10:44

Vir Biotechnology (NASDAQ:VIR) CAO Sells $70,324.32 in Stock

Vir Biotechnology Inc
Webhose 2026 Mar 21, 09:27

Hudson Bay Capital Management LP Grows Position in Vir Biotechnology, Inc. $VIR

Vir Biotechnology Inc
Webhose 2026 Mar 14, 08:43

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts

Vir Biotechnology Inc

VirBiotechnology news

Latest news

Info

Spread

0.08

Spread (%)

0.8658 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Wednesday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1447891328

Shares Outstanding

159811395

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.16

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now

Latest Education Articles

Trustpilot